Global VMAT2 Inhibitors Market Growth 2026-2032
The global VMAT2 Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington?s disease.
United States market for VMAT2 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for VMAT2 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for VMAT2 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key VMAT2 Inhibitors players cover Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc, Hetero, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?VMAT2 Inhibitors Industry Forecast? looks at past sales and reviews total world VMAT2 Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected VMAT2 Inhibitors sales for 2026 through 2032. With VMAT2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world VMAT2 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global VMAT2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on VMAT2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global VMAT2 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for VMAT2 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global VMAT2 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of VMAT2 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington?s disease.
United States market for VMAT2 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for VMAT2 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for VMAT2 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key VMAT2 Inhibitors players cover Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc, Hetero, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?VMAT2 Inhibitors Industry Forecast? looks at past sales and reviews total world VMAT2 Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected VMAT2 Inhibitors sales for 2026 through 2032. With VMAT2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world VMAT2 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global VMAT2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on VMAT2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global VMAT2 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for VMAT2 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global VMAT2 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of VMAT2 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Tetrabenazine
- Valbenazine
- Other
- Huntington?s Disease
- Tardive Dyskinesia
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Neurocrine Biosciences, Inc
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals plc
- Hetero
- Bausch Health Companies Inc
- Dr. Reddy's Laboratories Ltd
- Piramal Pharma Solution
- Lupin
- Luye Pharma Group
- What is the 10-year outlook for the global VMAT2 Inhibitors market?
- What factors are driving VMAT2 Inhibitors market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do VMAT2 Inhibitors market opportunities vary by end market size?
- How does VMAT2 Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global VMAT2 Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for VMAT2 Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for VMAT2 Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 VMAT2 Inhibitors Segment by Type
2.2.1 Tetrabenazine
2.2.2 Valbenazine
2.2.3 Other
2.2.4 VMAT2 Inhibitors Sales by Type
2.2.4.1 Global VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
2.2.4.2 Global VMAT2 Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global VMAT2 Inhibitors Sale Price by Type (2021-2026)
2.3 VMAT2 Inhibitors Segment by Application
2.3.1 Huntington?s Disease
2.3.2 Tardive Dyskinesia
2.3.3 Other
2.3.4 VMAT2 Inhibitors Sales by Application
2.3.4.1 Global VMAT2 Inhibitors Sale Market Share by Application (2021-2026)
2.3.4.2 Global VMAT2 Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global VMAT2 Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global VMAT2 Inhibitors Breakdown Data by Company
3.1.1 Global VMAT2 Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global VMAT2 Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global VMAT2 Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global VMAT2 Inhibitors Revenue by Company (2021-2026)
3.2.2 Global VMAT2 Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global VMAT2 Inhibitors Sale Price by Company
3.4 Key Manufacturers VMAT2 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers VMAT2 Inhibitors Product Location Distribution
3.4.2 Players VMAT2 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VMAT2 INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic VMAT2 Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global VMAT2 Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global VMAT2 Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic VMAT2 Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global VMAT2 Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global VMAT2 Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas VMAT2 Inhibitors Sales Growth
4.4 APAC VMAT2 Inhibitors Sales Growth
4.5 Europe VMAT2 Inhibitors Sales Growth
4.6 Middle East & Africa VMAT2 Inhibitors Sales Growth
5 AMERICAS
5.1 Americas VMAT2 Inhibitors Sales by Country
5.1.1 Americas VMAT2 Inhibitors Sales by Country (2021-2026)
5.1.2 Americas VMAT2 Inhibitors Revenue by Country (2021-2026)
5.2 Americas VMAT2 Inhibitors Sales by Type (2021-2026)
5.3 Americas VMAT2 Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VMAT2 Inhibitors Sales by Region
6.1.1 APAC VMAT2 Inhibitors Sales by Region (2021-2026)
6.1.2 APAC VMAT2 Inhibitors Revenue by Region (2021-2026)
6.2 APAC VMAT2 Inhibitors Sales by Type (2021-2026)
6.3 APAC VMAT2 Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe VMAT2 Inhibitors by Country
7.1.1 Europe VMAT2 Inhibitors Sales by Country (2021-2026)
7.1.2 Europe VMAT2 Inhibitors Revenue by Country (2021-2026)
7.2 Europe VMAT2 Inhibitors Sales by Type (2021-2026)
7.3 Europe VMAT2 Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa VMAT2 Inhibitors by Country
8.1.1 Middle East & Africa VMAT2 Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa VMAT2 Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa VMAT2 Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa VMAT2 Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of VMAT2 Inhibitors
10.3 Manufacturing Process Analysis of VMAT2 Inhibitors
10.4 Industry Chain Structure of VMAT2 Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 VMAT2 Inhibitors Distributors
11.3 VMAT2 Inhibitors Customer
12 WORLD FORECAST REVIEW FOR VMAT2 INHIBITORS BY GEOGRAPHIC REGION
12.1 Global VMAT2 Inhibitors Market Size Forecast by Region
12.1.1 Global VMAT2 Inhibitors Forecast by Region (2027-2032)
12.1.2 Global VMAT2 Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global VMAT2 Inhibitors Forecast by Type (2027-2032)
12.7 Global VMAT2 Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Neurocrine Biosciences, Inc
13.1.1 Neurocrine Biosciences, Inc Company Information
13.1.2 Neurocrine Biosciences, Inc VMAT2 Inhibitors Product Portfolios and Specifications
13.1.3 Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Neurocrine Biosciences, Inc Main Business Overview
13.1.5 Neurocrine Biosciences, Inc Latest Developments
13.2 Teva Pharmaceutical Industries Ltd
13.2.1 Teva Pharmaceutical Industries Ltd Company Information
13.2.2 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
13.2.3 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.2.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.3 Sun Pharmaceutical Industries Ltd
13.3.1 Sun Pharmaceutical Industries Ltd Company Information
13.3.2 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
13.3.3 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.3.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.4 Hikma Pharmaceuticals plc
13.4.1 Hikma Pharmaceuticals plc Company Information
13.4.2 Hikma Pharmaceuticals plc VMAT2 Inhibitors Product Portfolios and Specifications
13.4.3 Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Hikma Pharmaceuticals plc Main Business Overview
13.4.5 Hikma Pharmaceuticals plc Latest Developments
13.5 Hetero
13.5.1 Hetero Company Information
13.5.2 Hetero VMAT2 Inhibitors Product Portfolios and Specifications
13.5.3 Hetero VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Hetero Main Business Overview
13.5.5 Hetero Latest Developments
13.6 Bausch Health Companies Inc
13.6.1 Bausch Health Companies Inc Company Information
13.6.2 Bausch Health Companies Inc VMAT2 Inhibitors Product Portfolios and Specifications
13.6.3 Bausch Health Companies Inc VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bausch Health Companies Inc Main Business Overview
13.6.5 Bausch Health Companies Inc Latest Developments
13.7 Dr. Reddy's Laboratories Ltd
13.7.1 Dr. Reddy's Laboratories Ltd Company Information
13.7.2 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product Portfolios and Specifications
13.7.3 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Dr. Reddy's Laboratories Ltd Main Business Overview
13.7.5 Dr. Reddy's Laboratories Ltd Latest Developments
13.8 Piramal Pharma Solution
13.8.1 Piramal Pharma Solution Company Information
13.8.2 Piramal Pharma Solution VMAT2 Inhibitors Product Portfolios and Specifications
13.8.3 Piramal Pharma Solution VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Piramal Pharma Solution Main Business Overview
13.8.5 Piramal Pharma Solution Latest Developments
13.9 Lupin
13.9.1 Lupin Company Information
13.9.2 Lupin VMAT2 Inhibitors Product Portfolios and Specifications
13.9.3 Lupin VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Lupin Main Business Overview
13.9.5 Lupin Latest Developments
13.10 Luye Pharma Group
13.10.1 Luye Pharma Group Company Information
13.10.2 Luye Pharma Group VMAT2 Inhibitors Product Portfolios and Specifications
13.10.3 Luye Pharma Group VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Luye Pharma Group Main Business Overview
13.10.5 Luye Pharma Group Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global VMAT2 Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for VMAT2 Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for VMAT2 Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 VMAT2 Inhibitors Segment by Type
2.2.1 Tetrabenazine
2.2.2 Valbenazine
2.2.3 Other
2.2.4 VMAT2 Inhibitors Sales by Type
2.2.4.1 Global VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
2.2.4.2 Global VMAT2 Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global VMAT2 Inhibitors Sale Price by Type (2021-2026)
2.3 VMAT2 Inhibitors Segment by Application
2.3.1 Huntington?s Disease
2.3.2 Tardive Dyskinesia
2.3.3 Other
2.3.4 VMAT2 Inhibitors Sales by Application
2.3.4.1 Global VMAT2 Inhibitors Sale Market Share by Application (2021-2026)
2.3.4.2 Global VMAT2 Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global VMAT2 Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global VMAT2 Inhibitors Breakdown Data by Company
3.1.1 Global VMAT2 Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global VMAT2 Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global VMAT2 Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global VMAT2 Inhibitors Revenue by Company (2021-2026)
3.2.2 Global VMAT2 Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global VMAT2 Inhibitors Sale Price by Company
3.4 Key Manufacturers VMAT2 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers VMAT2 Inhibitors Product Location Distribution
3.4.2 Players VMAT2 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VMAT2 INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic VMAT2 Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global VMAT2 Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global VMAT2 Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic VMAT2 Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global VMAT2 Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global VMAT2 Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas VMAT2 Inhibitors Sales Growth
4.4 APAC VMAT2 Inhibitors Sales Growth
4.5 Europe VMAT2 Inhibitors Sales Growth
4.6 Middle East & Africa VMAT2 Inhibitors Sales Growth
5 AMERICAS
5.1 Americas VMAT2 Inhibitors Sales by Country
5.1.1 Americas VMAT2 Inhibitors Sales by Country (2021-2026)
5.1.2 Americas VMAT2 Inhibitors Revenue by Country (2021-2026)
5.2 Americas VMAT2 Inhibitors Sales by Type (2021-2026)
5.3 Americas VMAT2 Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VMAT2 Inhibitors Sales by Region
6.1.1 APAC VMAT2 Inhibitors Sales by Region (2021-2026)
6.1.2 APAC VMAT2 Inhibitors Revenue by Region (2021-2026)
6.2 APAC VMAT2 Inhibitors Sales by Type (2021-2026)
6.3 APAC VMAT2 Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe VMAT2 Inhibitors by Country
7.1.1 Europe VMAT2 Inhibitors Sales by Country (2021-2026)
7.1.2 Europe VMAT2 Inhibitors Revenue by Country (2021-2026)
7.2 Europe VMAT2 Inhibitors Sales by Type (2021-2026)
7.3 Europe VMAT2 Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa VMAT2 Inhibitors by Country
8.1.1 Middle East & Africa VMAT2 Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa VMAT2 Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa VMAT2 Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa VMAT2 Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of VMAT2 Inhibitors
10.3 Manufacturing Process Analysis of VMAT2 Inhibitors
10.4 Industry Chain Structure of VMAT2 Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 VMAT2 Inhibitors Distributors
11.3 VMAT2 Inhibitors Customer
12 WORLD FORECAST REVIEW FOR VMAT2 INHIBITORS BY GEOGRAPHIC REGION
12.1 Global VMAT2 Inhibitors Market Size Forecast by Region
12.1.1 Global VMAT2 Inhibitors Forecast by Region (2027-2032)
12.1.2 Global VMAT2 Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global VMAT2 Inhibitors Forecast by Type (2027-2032)
12.7 Global VMAT2 Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Neurocrine Biosciences, Inc
13.1.1 Neurocrine Biosciences, Inc Company Information
13.1.2 Neurocrine Biosciences, Inc VMAT2 Inhibitors Product Portfolios and Specifications
13.1.3 Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Neurocrine Biosciences, Inc Main Business Overview
13.1.5 Neurocrine Biosciences, Inc Latest Developments
13.2 Teva Pharmaceutical Industries Ltd
13.2.1 Teva Pharmaceutical Industries Ltd Company Information
13.2.2 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
13.2.3 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.2.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.3 Sun Pharmaceutical Industries Ltd
13.3.1 Sun Pharmaceutical Industries Ltd Company Information
13.3.2 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
13.3.3 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.3.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.4 Hikma Pharmaceuticals plc
13.4.1 Hikma Pharmaceuticals plc Company Information
13.4.2 Hikma Pharmaceuticals plc VMAT2 Inhibitors Product Portfolios and Specifications
13.4.3 Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Hikma Pharmaceuticals plc Main Business Overview
13.4.5 Hikma Pharmaceuticals plc Latest Developments
13.5 Hetero
13.5.1 Hetero Company Information
13.5.2 Hetero VMAT2 Inhibitors Product Portfolios and Specifications
13.5.3 Hetero VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Hetero Main Business Overview
13.5.5 Hetero Latest Developments
13.6 Bausch Health Companies Inc
13.6.1 Bausch Health Companies Inc Company Information
13.6.2 Bausch Health Companies Inc VMAT2 Inhibitors Product Portfolios and Specifications
13.6.3 Bausch Health Companies Inc VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bausch Health Companies Inc Main Business Overview
13.6.5 Bausch Health Companies Inc Latest Developments
13.7 Dr. Reddy's Laboratories Ltd
13.7.1 Dr. Reddy's Laboratories Ltd Company Information
13.7.2 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product Portfolios and Specifications
13.7.3 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Dr. Reddy's Laboratories Ltd Main Business Overview
13.7.5 Dr. Reddy's Laboratories Ltd Latest Developments
13.8 Piramal Pharma Solution
13.8.1 Piramal Pharma Solution Company Information
13.8.2 Piramal Pharma Solution VMAT2 Inhibitors Product Portfolios and Specifications
13.8.3 Piramal Pharma Solution VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Piramal Pharma Solution Main Business Overview
13.8.5 Piramal Pharma Solution Latest Developments
13.9 Lupin
13.9.1 Lupin Company Information
13.9.2 Lupin VMAT2 Inhibitors Product Portfolios and Specifications
13.9.3 Lupin VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Lupin Main Business Overview
13.9.5 Lupin Latest Developments
13.10 Luye Pharma Group
13.10.1 Luye Pharma Group Company Information
13.10.2 Luye Pharma Group VMAT2 Inhibitors Product Portfolios and Specifications
13.10.3 Luye Pharma Group VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Luye Pharma Group Main Business Overview
13.10.5 Luye Pharma Group Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. VMAT2 Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. VMAT2 Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tetrabenazine
Table 4. Major Players of Valbenazine
Table 5. Major Players of Other
Table 6. Global VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 7. Global VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Table 8. Global VMAT2 Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 9. Global VMAT2 Inhibitors Revenue Market Share by Type (2021-2026)
Table 10. Global VMAT2 Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global VMAT2 Inhibitors Sale by Application (2021-2026) & (K Units)
Table 12. Global VMAT2 Inhibitors Sale Market Share by Application (2021-2026)
Table 13. Global VMAT2 Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 14. Global VMAT2 Inhibitors Revenue Market Share by Application (2021-2026)
Table 15. Global VMAT2 Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global VMAT2 Inhibitors Sales by Company (2021-2026) & (K Units)
Table 17. Global VMAT2 Inhibitors Sales Market Share by Company (2021-2026)
Table 18. Global VMAT2 Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 19. Global VMAT2 Inhibitors Revenue Market Share by Company (2021-2026)
Table 20. Global VMAT2 Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers VMAT2 Inhibitors Producing Area Distribution and Sales Area
Table 22. Players VMAT2 Inhibitors Products Offered
Table 23. VMAT2 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global VMAT2 Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global VMAT2 Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 28. Global VMAT2 Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global VMAT2 Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global VMAT2 Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global VMAT2 Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 32. Global VMAT2 Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global VMAT2 Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas VMAT2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 35. Americas VMAT2 Inhibitors Sales Market Share by Country (2021-2026)
Table 36. Americas VMAT2 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 38. Americas VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 39. APAC VMAT2 Inhibitors Sales by Region (2021-2026) & (K Units)
Table 40. APAC VMAT2 Inhibitors Sales Market Share by Region (2021-2026)
Table 41. APAC VMAT2 Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 43. APAC VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 44. Europe VMAT2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 45. Europe VMAT2 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. Europe VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa VMAT2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa VMAT2 Inhibitors Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of VMAT2 Inhibitors
Table 53. Key Market Challenges & Risks of VMAT2 Inhibitors
Table 54. Key Industry Trends of VMAT2 Inhibitors
Table 55. VMAT2 Inhibitors Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. VMAT2 Inhibitors Distributors List
Table 58. VMAT2 Inhibitors Customer List
Table 59. Global VMAT2 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global VMAT2 Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas VMAT2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas VMAT2 Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC VMAT2 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC VMAT2 Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe VMAT2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe VMAT2 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa VMAT2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa VMAT2 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global VMAT2 Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global VMAT2 Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global VMAT2 Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global VMAT2 Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Neurocrine Biosciences, Inc Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 74. Neurocrine Biosciences, Inc VMAT2 Inhibitors Product Portfolios and Specifications
Table 75. Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Neurocrine Biosciences, Inc Main Business
Table 77. Neurocrine Biosciences, Inc Latest Developments
Table 78. Teva Pharmaceutical Industries Ltd Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
Table 80. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Teva Pharmaceutical Industries Ltd Main Business
Table 82. Teva Pharmaceutical Industries Ltd Latest Developments
Table 83. Sun Pharmaceutical Industries Ltd Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
Table 85. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sun Pharmaceutical Industries Ltd Main Business
Table 87. Sun Pharmaceutical Industries Ltd Latest Developments
Table 88. Hikma Pharmaceuticals plc Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Hikma Pharmaceuticals plc VMAT2 Inhibitors Product Portfolios and Specifications
Table 90. Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Hikma Pharmaceuticals plc Main Business
Table 92. Hikma Pharmaceuticals plc Latest Developments
Table 93. Hetero Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. Hetero VMAT2 Inhibitors Product Portfolios and Specifications
Table 95. Hetero VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Hetero Main Business
Table 97. Hetero Latest Developments
Table 98. Bausch Health Companies Inc Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Bausch Health Companies Inc VMAT2 Inhibitors Product Portfolios and Specifications
Table 100. Bausch Health Companies Inc VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Bausch Health Companies Inc Main Business
Table 102. Bausch Health Companies Inc Latest Developments
Table 103. Dr. Reddy's Laboratories Ltd Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product Portfolios and Specifications
Table 105. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Dr. Reddy's Laboratories Ltd Main Business
Table 107. Dr. Reddy's Laboratories Ltd Latest Developments
Table 108. Piramal Pharma Solution Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Piramal Pharma Solution VMAT2 Inhibitors Product Portfolios and Specifications
Table 110. Piramal Pharma Solution VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Piramal Pharma Solution Main Business
Table 112. Piramal Pharma Solution Latest Developments
Table 113. Lupin Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Lupin VMAT2 Inhibitors Product Portfolios and Specifications
Table 115. Lupin VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Lupin Main Business
Table 117. Lupin Latest Developments
Table 118. Luye Pharma Group Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Luye Pharma Group VMAT2 Inhibitors Product Portfolios and Specifications
Table 120. Luye Pharma Group VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Luye Pharma Group Main Business
Table 122. Luye Pharma Group Latest Developments
Table 1. VMAT2 Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. VMAT2 Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tetrabenazine
Table 4. Major Players of Valbenazine
Table 5. Major Players of Other
Table 6. Global VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 7. Global VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Table 8. Global VMAT2 Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 9. Global VMAT2 Inhibitors Revenue Market Share by Type (2021-2026)
Table 10. Global VMAT2 Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global VMAT2 Inhibitors Sale by Application (2021-2026) & (K Units)
Table 12. Global VMAT2 Inhibitors Sale Market Share by Application (2021-2026)
Table 13. Global VMAT2 Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 14. Global VMAT2 Inhibitors Revenue Market Share by Application (2021-2026)
Table 15. Global VMAT2 Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global VMAT2 Inhibitors Sales by Company (2021-2026) & (K Units)
Table 17. Global VMAT2 Inhibitors Sales Market Share by Company (2021-2026)
Table 18. Global VMAT2 Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 19. Global VMAT2 Inhibitors Revenue Market Share by Company (2021-2026)
Table 20. Global VMAT2 Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers VMAT2 Inhibitors Producing Area Distribution and Sales Area
Table 22. Players VMAT2 Inhibitors Products Offered
Table 23. VMAT2 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global VMAT2 Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global VMAT2 Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 28. Global VMAT2 Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global VMAT2 Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global VMAT2 Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global VMAT2 Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 32. Global VMAT2 Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global VMAT2 Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas VMAT2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 35. Americas VMAT2 Inhibitors Sales Market Share by Country (2021-2026)
Table 36. Americas VMAT2 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 38. Americas VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 39. APAC VMAT2 Inhibitors Sales by Region (2021-2026) & (K Units)
Table 40. APAC VMAT2 Inhibitors Sales Market Share by Region (2021-2026)
Table 41. APAC VMAT2 Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 43. APAC VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 44. Europe VMAT2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 45. Europe VMAT2 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. Europe VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa VMAT2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa VMAT2 Inhibitors Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa VMAT2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa VMAT2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of VMAT2 Inhibitors
Table 53. Key Market Challenges & Risks of VMAT2 Inhibitors
Table 54. Key Industry Trends of VMAT2 Inhibitors
Table 55. VMAT2 Inhibitors Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. VMAT2 Inhibitors Distributors List
Table 58. VMAT2 Inhibitors Customer List
Table 59. Global VMAT2 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global VMAT2 Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas VMAT2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas VMAT2 Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC VMAT2 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC VMAT2 Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe VMAT2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe VMAT2 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa VMAT2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa VMAT2 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global VMAT2 Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global VMAT2 Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global VMAT2 Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global VMAT2 Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Neurocrine Biosciences, Inc Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 74. Neurocrine Biosciences, Inc VMAT2 Inhibitors Product Portfolios and Specifications
Table 75. Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Neurocrine Biosciences, Inc Main Business
Table 77. Neurocrine Biosciences, Inc Latest Developments
Table 78. Teva Pharmaceutical Industries Ltd Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
Table 80. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Teva Pharmaceutical Industries Ltd Main Business
Table 82. Teva Pharmaceutical Industries Ltd Latest Developments
Table 83. Sun Pharmaceutical Industries Ltd Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product Portfolios and Specifications
Table 85. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sun Pharmaceutical Industries Ltd Main Business
Table 87. Sun Pharmaceutical Industries Ltd Latest Developments
Table 88. Hikma Pharmaceuticals plc Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Hikma Pharmaceuticals plc VMAT2 Inhibitors Product Portfolios and Specifications
Table 90. Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Hikma Pharmaceuticals plc Main Business
Table 92. Hikma Pharmaceuticals plc Latest Developments
Table 93. Hetero Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. Hetero VMAT2 Inhibitors Product Portfolios and Specifications
Table 95. Hetero VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Hetero Main Business
Table 97. Hetero Latest Developments
Table 98. Bausch Health Companies Inc Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Bausch Health Companies Inc VMAT2 Inhibitors Product Portfolios and Specifications
Table 100. Bausch Health Companies Inc VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Bausch Health Companies Inc Main Business
Table 102. Bausch Health Companies Inc Latest Developments
Table 103. Dr. Reddy's Laboratories Ltd Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product Portfolios and Specifications
Table 105. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Dr. Reddy's Laboratories Ltd Main Business
Table 107. Dr. Reddy's Laboratories Ltd Latest Developments
Table 108. Piramal Pharma Solution Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Piramal Pharma Solution VMAT2 Inhibitors Product Portfolios and Specifications
Table 110. Piramal Pharma Solution VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Piramal Pharma Solution Main Business
Table 112. Piramal Pharma Solution Latest Developments
Table 113. Lupin Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Lupin VMAT2 Inhibitors Product Portfolios and Specifications
Table 115. Lupin VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Lupin Main Business
Table 117. Lupin Latest Developments
Table 118. Luye Pharma Group Basic Information, VMAT2 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Luye Pharma Group VMAT2 Inhibitors Product Portfolios and Specifications
Table 120. Luye Pharma Group VMAT2 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Luye Pharma Group Main Business
Table 122. Luye Pharma Group Latest Developments
LIST OF FIGURES
Figure 1. Picture of VMAT2 Inhibitors
Figure 2. VMAT2 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global VMAT2 Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global VMAT2 Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. VMAT2 Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. VMAT2 Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. VMAT2 Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Tetrabenazine
Figure 12. Product Picture of Valbenazine
Figure 13. Product Picture of Other
Figure 14. Global VMAT2 Inhibitors Sales Market Share by Type in 2026
Figure 15. Global VMAT2 Inhibitors Revenue Market Share by Type (2021-2026)
Figure 16. VMAT2 Inhibitors Consumed in Huntington?s Disease
Figure 17. Global VMAT2 Inhibitors Market: Huntington?s Disease (2021-2026) & (K Units)
Figure 18. VMAT2 Inhibitors Consumed in Tardive Dyskinesia
Figure 19. Global VMAT2 Inhibitors Market: Tardive Dyskinesia (2021-2026) & (K Units)
Figure 20. VMAT2 Inhibitors Consumed in Other
Figure 21. Global VMAT2 Inhibitors Market: Other (2021-2026) & (K Units)
Figure 22. Global VMAT2 Inhibitors Sale Market Share by Application (2025)
Figure 23. Global VMAT2 Inhibitors Revenue Market Share by Application in 2026
Figure 24. VMAT2 Inhibitors Sales by Company in 2026 (K Units)
Figure 25. Global VMAT2 Inhibitors Sales Market Share by Company in 2026
Figure 26. VMAT2 Inhibitors Revenue by Company in 2026 ($ millions)
Figure 27. Global VMAT2 Inhibitors Revenue Market Share by Company in 2026
Figure 28. Global VMAT2 Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global VMAT2 Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 30. Americas VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 31. Americas VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 32. APAC VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 33. APAC VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 34. Europe VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 35. Europe VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Americas VMAT2 Inhibitors Sales Market Share by Country in 2026
Figure 39. Americas VMAT2 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 40. Americas VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 41. Americas VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 42. United States VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC VMAT2 Inhibitors Sales Market Share by Region in 2026
Figure 47. APAC VMAT2 Inhibitors Revenue Market Share by Region (2021-2026)
Figure 48. APAC VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 49. APAC VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 50. China VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. India VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe VMAT2 Inhibitors Sales Market Share by Country in 2026
Figure 58. Europe VMAT2 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 59. Europe VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 60. Europe VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 61. Germany VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 62. France VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 63. UK VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa VMAT2 Inhibitors Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 69. Egypt VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of VMAT2 Inhibitors in 2026
Figure 75. Manufacturing Process Analysis of VMAT2 Inhibitors
Figure 76. Industry Chain Structure of VMAT2 Inhibitors
Figure 77. Channels of Distribution
Figure 78. Global VMAT2 Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 79. Global VMAT2 Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global VMAT2 Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global VMAT2 Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global VMAT2 Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global VMAT2 Inhibitors Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of VMAT2 Inhibitors
Figure 2. VMAT2 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global VMAT2 Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global VMAT2 Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. VMAT2 Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. VMAT2 Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. VMAT2 Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Tetrabenazine
Figure 12. Product Picture of Valbenazine
Figure 13. Product Picture of Other
Figure 14. Global VMAT2 Inhibitors Sales Market Share by Type in 2026
Figure 15. Global VMAT2 Inhibitors Revenue Market Share by Type (2021-2026)
Figure 16. VMAT2 Inhibitors Consumed in Huntington?s Disease
Figure 17. Global VMAT2 Inhibitors Market: Huntington?s Disease (2021-2026) & (K Units)
Figure 18. VMAT2 Inhibitors Consumed in Tardive Dyskinesia
Figure 19. Global VMAT2 Inhibitors Market: Tardive Dyskinesia (2021-2026) & (K Units)
Figure 20. VMAT2 Inhibitors Consumed in Other
Figure 21. Global VMAT2 Inhibitors Market: Other (2021-2026) & (K Units)
Figure 22. Global VMAT2 Inhibitors Sale Market Share by Application (2025)
Figure 23. Global VMAT2 Inhibitors Revenue Market Share by Application in 2026
Figure 24. VMAT2 Inhibitors Sales by Company in 2026 (K Units)
Figure 25. Global VMAT2 Inhibitors Sales Market Share by Company in 2026
Figure 26. VMAT2 Inhibitors Revenue by Company in 2026 ($ millions)
Figure 27. Global VMAT2 Inhibitors Revenue Market Share by Company in 2026
Figure 28. Global VMAT2 Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global VMAT2 Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 30. Americas VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 31. Americas VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 32. APAC VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 33. APAC VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 34. Europe VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 35. Europe VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa VMAT2 Inhibitors Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa VMAT2 Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Americas VMAT2 Inhibitors Sales Market Share by Country in 2026
Figure 39. Americas VMAT2 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 40. Americas VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 41. Americas VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 42. United States VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC VMAT2 Inhibitors Sales Market Share by Region in 2026
Figure 47. APAC VMAT2 Inhibitors Revenue Market Share by Region (2021-2026)
Figure 48. APAC VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 49. APAC VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 50. China VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. India VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe VMAT2 Inhibitors Sales Market Share by Country in 2026
Figure 58. Europe VMAT2 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 59. Europe VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 60. Europe VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 61. Germany VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 62. France VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 63. UK VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa VMAT2 Inhibitors Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa VMAT2 Inhibitors Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa VMAT2 Inhibitors Sales Market Share by Application (2021-2026)
Figure 69. Egypt VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries VMAT2 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of VMAT2 Inhibitors in 2026
Figure 75. Manufacturing Process Analysis of VMAT2 Inhibitors
Figure 76. Industry Chain Structure of VMAT2 Inhibitors
Figure 77. Channels of Distribution
Figure 78. Global VMAT2 Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 79. Global VMAT2 Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global VMAT2 Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global VMAT2 Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global VMAT2 Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global VMAT2 Inhibitors Revenue Market Share Forecast by Application (2027-2032)
